ArticleJAMA network open2021

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.

Hengwei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.